These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 30034528

  • 21. Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.
    Jukic T, Drobne D, Pusavec S, Ihan A, Stubljar D, Starc A.
    Med Sci Monit; 2023 Feb 18; 29():e939084. PubMed ID: 36807319
    [Abstract] [Full Text] [Related]

  • 22. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits.
    Laserna-Mendieta EJ, Salvador-Martín S, Arias-González L, Ruiz-Ponce M, Menchén LA, Sánchez C, López-Fernández LA, Lucendo AJ.
    Clin Chem Lab Med; 2019 Nov 26; 57(12):1906-1914. PubMed ID: 31085742
    [Abstract] [Full Text] [Related]

  • 23. Lateral flow test versus enzyme-linked immunosorbent assay to measure infliximab trough concentrations: A head-to-head comparison.
    Bouhuys M, Wessels MMS, de Vries W, Lambeck AJA, Touw DJ, van Rheenen PF.
    J Pediatr Gastroenterol Nutr; 2024 Dec 26; 79(6):1134-1141. PubMed ID: 39390697
    [Abstract] [Full Text] [Related]

  • 24. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
    Nasser Y, Labetoulle R, Harzallah I, Berger AE, Roblin X, Paul S.
    Dig Dis Sci; 2018 Oct 26; 63(10):2714-2721. PubMed ID: 29948562
    [Abstract] [Full Text] [Related]

  • 25. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
    Laserna-Mendieta EJ, Salvador-Martín S, Marín-Jiménez I, Menchén LA, López-Cauce B, López-Fernández LA, Lucendo AJ.
    J Pharm Biomed Anal; 2021 May 10; 198():114003. PubMed ID: 33714800
    [Abstract] [Full Text] [Related]

  • 26. Intermittent Appearance of Antibodies to Infliximab Is Not Associated With Reduced Efficacy in Patients With Inflammatory Bowel Diseases.
    Awadie H, Waterman M.
    J Clin Gastroenterol; 2022 Jan 01; 56(1):e47-e51. PubMed ID: 33252556
    [Abstract] [Full Text] [Related]

  • 27. Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges.
    Cheli S, Savino D, Penagini F, Zuccotti G, Zuin G, Clementi E, Cattaneo D.
    Pharmaceutics; 2023 Jun 27; 15(7):. PubMed ID: 37514022
    [Abstract] [Full Text] [Related]

  • 28. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.
    Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, van der Kleij D, Gils A, Dijkstra G.
    Aliment Pharmacol Ther; 2012 Oct 27; 36(8):765-71. PubMed ID: 22928581
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Development of a C1q-immobilized (Cim) assay to measure total antibodies to infliximab and its clinical relevance in patients with inflammatory bowel disease.
    Yoshimura N, Yokoyama Y, Sako M, Aoyama N, Hirai F, Sawada K, Kashiwagi N, Suzuki Y.
    Cytokine; 2019 Aug 27; 120():54-61. PubMed ID: 31003189
    [Abstract] [Full Text] [Related]

  • 32. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
    Coutzac C, Chapuis J, Poullenot F, Chabrun E, Capdepont M, Blanco P, Laharie D.
    J Crohns Colitis; 2015 Nov 27; 9(11):982-7. PubMed ID: 26351388
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.
    Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D, Colombel JF, Allez M.
    Inflamm Bowel Dis; 2012 Jul 27; 18(7):1199-206. PubMed ID: 22127789
    [Abstract] [Full Text] [Related]

  • 35. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
    Fiorino G, Ruiz-Argüello MB, Maguregui A, Nagore D, Correale C, Radice S, Gilardi D, Allocca M, Furfaro F, Martínez A, Danese S.
    Inflamm Bowel Dis; 2018 Feb 15; 24(3):601-606. PubMed ID: 29462398
    [Abstract] [Full Text] [Related]

  • 36. The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study.
    Langford T, Arkir Z, Chalkidou A, Goddard K, Kaftantzi L, Samaan M, Irving P.
    JMIR Res Protoc; 2018 Oct 19; 7(10):e11218. PubMed ID: 30341052
    [Abstract] [Full Text] [Related]

  • 37. A Dutch regional trauma registry: quality check of the registered data.
    Olthof DC, Luitse JS, de Groot FM, Goslings JC.
    BMJ Qual Saf; 2013 Sep 19; 22(9):752-8. PubMed ID: 23674693
    [Abstract] [Full Text] [Related]

  • 38. Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501).
    Francois F, Naimi L, Roblin X, Berger AE, Paul S.
    BMC Immunol; 2021 Dec 25; 22(1):81. PubMed ID: 34953484
    [Abstract] [Full Text] [Related]

  • 39. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
    Jourdil JF, Lebert D, Gautier-Veyret E, Lemaitre F, Bonaz B, Picard G, Tonini J, Stanke-Labesque F.
    Anal Bioanal Chem; 2017 Feb 25; 409(5):1195-1205. PubMed ID: 27826630
    [Abstract] [Full Text] [Related]

  • 40. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.
    Rolandsdotter H, Marits P, Sundin U, Wikström AC, Fagerberg UL, Finkel Y, Eberhardson M.
    Int J Mol Sci; 2017 Mar 07; 18(3):. PubMed ID: 28272355
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.